Moody Aldrich Partners LLC Makes New $3.90 Million Investment in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Moody Aldrich Partners LLC bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 63,114 shares of the company's stock, valued at approximately $3,904,000. Moody Aldrich Partners LLC owned about 0.13% of Amphastar Pharmaceuticals at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of AMPH. BlackRock Inc. lifted its position in Amphastar Pharmaceuticals by 1.1% in the third quarter. BlackRock Inc. now owns 7,147,813 shares of the company's stock valued at $200,854,000 after purchasing an additional 75,616 shares during the last quarter. Federated Hermes Inc. lifted its position in Amphastar Pharmaceuticals by 0.7% in the first quarter. Federated Hermes Inc. now owns 3,487,430 shares of the company's stock valued at $125,199,000 after purchasing an additional 23,095 shares during the last quarter. Vanguard Group Inc. lifted its position in Amphastar Pharmaceuticals by 1.8% in the third quarter. Vanguard Group Inc. now owns 2,606,162 shares of the company's stock valued at $73,234,000 after purchasing an additional 45,385 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 2.7% in the first quarter. Dimensional Fund Advisors LP now owns 1,917,571 shares of the company's stock valued at $71,909,000 after purchasing an additional 51,027 shares during the last quarter. Finally, State Street Corp lifted its position in Amphastar Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 1,540,846 shares of the company's stock valued at $53,606,000 after purchasing an additional 218,895 shares during the last quarter. Institutional investors own 65.09% of the company's stock.

Insider Buying and Selling

In related news, Director Floyd F. Petersen sold 500 shares of the company's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the sale, the director now directly owns 80,333 shares of the company's stock, valued at $4,265,682.30. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, COO Mary Z. Luo sold 131,386 shares of the company's stock in a transaction on Wednesday, January 10th. The stock was sold at an average price of $54.59, for a total value of $7,172,361.74. Following the sale, the chief operating officer now directly owns 1,104,416 shares of the company's stock, valued at $60,290,069.44. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Floyd F. Petersen sold 500 shares of the company's stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $53.10, for a total value of $26,550.00. Following the completion of the sale, the director now directly owns 80,333 shares in the company, valued at $4,265,682.30. The disclosure for this sale can be found here. Insiders have sold a total of 145,386 shares of company stock valued at $7,833,222 over the last ninety days. Company insiders own 27.80% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, February 29th. JPMorgan Chase & Co. started coverage on Amphastar Pharmaceuticals in a research report on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price objective for the company.

Amphastar Pharmaceuticals Trading Down 0.4 %

Shares of AMPH traded down $0.15 during mid-day trading on Tuesday, hitting $40.90. 279,728 shares of the company's stock traded hands, compared to its average volume of 472,518. The company has a quick ratio of 1.70, a current ratio of 2.17 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 1 year low of $35.62 and a 1 year high of $67.66. The firm has a market capitalization of $1.97 billion, a P/E ratio of 15.87, a PEG ratio of 0.99 and a beta of 0.85. The business's 50-day moving average price is $48.39 and its 200-day moving average price is $51.55.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last posted its earnings results on Wednesday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The business had revenue of $178.11 million for the quarter, compared to analysts' expectations of $174.90 million. As a group, sell-side analysts forecast that Amphastar Pharmaceuticals, Inc. will post 3.44 EPS for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.